Direct observation of G-protein binding to the human δ-opioid receptor using plasmon-waveguide resonance spectroscopy

被引:70
作者
Alves, ID
Salamon, Z
Varga, E
Yamamura, HI
Tollin, G
Hruby, VJ
机构
[1] Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA
[2] Univ Arizona, Dept Pharmacol, Tucson, AZ 85721 USA
[3] Univ Arizona, Dept Chem, Tucson, AZ 85721 USA
关键词
D O I
10.1074/jbc.M306866200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Using a recently developed method (Salamon, Z., Macleod, H. A., and Tollin, G. (1997) Biophys. J. 73, 2791 - 2797), plasmon-waveguide resonance spectroscopy, we have been able, for the first time, to directly measure the binding between the human brain delta-opioid receptor (hDOR) and its G-protein effectors in real-time. We have found that the affinity of the G-proteins toward the receptor is highly dependent on the nature of the ligand pre-bound to the receptor. The highest affinity was observed when the receptor was bound to an agonist (similar to10 nM); the lowest when receptor was bound to an antagonist (similar to 500 nM); and no binding at all was observed when the receptor was bound to an inverse agonist. We also have found direct evidence for the existence of an additional G-protein binding conformational state that corresponds to the unliganded receptor, which has a G-protein binding affinity of similar to 60 nM. Furthermore, GTP binding to the receptor . G-protein complex was only observed when the agonist was pre-bound. Similar studies were carried out using the individual G-protein subtypes for both the agonist and the unliganded receptor. Significant selectivity toward the different G-protein subtypes was observed. Thus, the unliganded receptor had highest affinity toward the Galpha(o) (K-d similar to 20 nM) and lowest affinity toward the Galpha(i2) (similar to 590 nM) subtypes, whereas the agonist-bound state had highest affinity for the Galpha(o) and Galpha(i2) subtypes (K-d similar to 9 nM and similar to 7 nM, respectively). GTP binding was also highly selective, both with respect to ligand and G-protein subtype. We believe that this methodology provides a powerful new way of investigating transmembrane signaling.
引用
收藏
页码:48890 / 48897
页数:8
相关论文
共 37 条
  • [1] Micropatterned immobilization of a G protein-coupled receptor and direct detection of G protein activation
    Bieri, C
    Ernst, OP
    Heyse, S
    Hofmann, KP
    Vogel, H
    [J]. NATURE BIOTECHNOLOGY, 1999, 17 (11) : 1105 - 1108
  • [2] Cannabinoid receptor agonist efficacy for stimulating [35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity
    Breivogel, CS
    Selley, DE
    Childers, SR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (27) : 16865 - 16873
  • [3] Brown GP, 1998, J PHARMACOL EXP THER, V286, P376
  • [4] Dominant-negative activity of an α1B-adrenergic receptor signal-inactivating point mutation
    Chen, SH
    Lin, F
    Xu, M
    Hwa, J
    Graham, RM
    [J]. EMBO JOURNAL, 2000, 19 (16) : 4265 - 4271
  • [5] Functional coupling of the human dopamine D2 receptor with Gαi1, Gαi2, Gαi3 and Gαo G proteins:: evidence for agonist regulation of G protein selectivity
    Gazi, L
    Nickolls, SA
    Strange, PG
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2003, 138 (05) : 775 - 786
  • [6] Structural instability of a constitutively active G protein-coupled receptor - Agonist-independent activation due to conformational flexibility
    Gether, U
    Ballesteros, JA
    Seifert, R
    SandersBush, E
    Weinstein, H
    Kobilka, BK
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (05) : 2587 - 2590
  • [7] Functionally different agonists induce distinct conformations in the G protein coupling domain of the β2 adrenergic receptor
    Ghanouni, P
    Gryczynski, Z
    Steenhuis, JJ
    Lee, TW
    Farrens, DL
    Lakowicz, JR
    Kobilka, BK
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (27) : 24433 - 24436
  • [8] Drug efficacy at G protein-coupled receptors
    Kenakin, T
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2002, 42 : 349 - 379
  • [9] Efficacy at G-protein-coupled receptors
    Kenakin, T
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (02) : 103 - 110
  • [10] KNAPP RJ, 1994, LIFE SCI, V54, P463